Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Biotech
ASH: Novartis details ianalumab's phase 3 rare blood disease win
If the combo therapy's boosted platelet counts persist even longer, it could "change the treatment paradigm" for primary immune thrombocytopenia.
Darren Incorvaia
Dec 9, 2025 7:30am
ASH: Star antibody sparkles in preview of possible ph. 3 success
Dec 7, 2025 9:40am
Hemab raises $157M series C for rare bleeding disorder goals
Oct 27, 2025 6:00am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
ASH surveys identify barriers to improving diversity in research
Dec 16, 2024 5:10pm
Sanofi BTK inhibitor for blood disease raises platelet levels
Nov 5, 2024 1:42pm
